Scpharmaceuticals Stock Fundamentals
| SCPH Stock | USD 3.03 0.04 1.34% |
Scpharmaceuticals fundamentals help investors to digest information that contributes to Scpharmaceuticals' financial success or failures. It also enables traders to predict the movement of Scpharmaceuticals Stock. The fundamental analysis module provides a way to measure Scpharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Scpharmaceuticals stock.
As of now, Scpharmaceuticals' Gross Profit is increasing as compared to previous years. The Scpharmaceuticals' current Other Operating Expenses is estimated to increase to about 83.3 M, while Depreciation And Amortization is projected to decrease to under 502.9 K. Scpharmaceuticals | Select Account or Indicator |
Scpharmaceuticals Company Return On Equity Analysis
Scpharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Scpharmaceuticals Return On Equity | -2.01 |
Most of Scpharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scpharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Scpharmaceuticals Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Scpharmaceuticals has a Return On Equity of -2.0065. This is 91.63% lower than that of the Pharmaceuticals sector and 94.5% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Scpharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Scpharmaceuticals's current stock value. Our valuation model uses many indicators to compare Scpharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Scpharmaceuticals competition to find correlations between indicators driving Scpharmaceuticals's intrinsic value. More Info.Scpharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Scpharmaceuticals' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Scpharmaceuticals' earnings, one of the primary drivers of an investment's value.Scpharmaceuticals Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scpharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Scpharmaceuticals could also be used in its relative valuation, which is a method of valuing Scpharmaceuticals by comparing valuation metrics of similar companies.Scpharmaceuticals is currently under evaluation in return on equity category among its peers.
Scpharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Scpharmaceuticals from analyzing Scpharmaceuticals' financial statements. These drivers represent accounts that assess Scpharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Scpharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 130.0M | 137.3M | 203.3M | 241.5M | 217.3M | 110.1M | |
| Enterprise Value | 44.9M | 80.7M | 169.6M | 234.9M | 211.4M | 222.0M |
Scpharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Scpharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Scpharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Scpharmaceuticals Fundamentals
| Return On Equity | -2.01 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | (2.65) % | ||||
| Operating Margin | (1.81) % | ||||
| Current Valuation | 110.63 M | ||||
| Shares Outstanding | 50.04 M | ||||
| Shares Owned By Insiders | 11.21 % | ||||
| Shares Owned By Institutions | 85.33 % | ||||
| Number Of Shares Shorted | 6.14 M | ||||
| Price To Book | 4.87 X | ||||
| Price To Sales | 5.01 X | ||||
| Revenue | 13.59 M | ||||
| Gross Profit | 21.11 M | ||||
| EBITDA | (46.06 M) | ||||
| Net Income | (54.81 M) | ||||
| Cash And Equivalents | 55.85 M | ||||
| Cash Per Share | 2.04 X | ||||
| Total Debt | 40.27 M | ||||
| Debt To Equity | 0.32 % | ||||
| Current Ratio | 3.72 X | ||||
| Book Value Per Share | 0.61 X | ||||
| Cash Flow From Operations | (59.24 M) | ||||
| Short Ratio | 22.58 X | ||||
| Earnings Per Share | (1.95) X | ||||
| Target Price | 17.5 | ||||
| Number Of Employees | 135 | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 151.62 M | ||||
| Total Asset | 94.48 M | ||||
| Retained Earnings | (281.35 M) | ||||
| Working Capital | 79.8 M | ||||
| Net Asset | 94.48 M |
About Scpharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Scpharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scpharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scpharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 65.7 K | 62.4 K | |
| Total Revenue | 15.6 M | 16.4 M | |
| Cost Of Revenue | 4.4 M | 4.6 M | |
| Stock Based Compensation To Revenue | 0.32 | 0.29 | |
| Sales General And Administrative To Revenue | 3.53 | 3.14 | |
| Research And Ddevelopement To Revenue | 0.78 | 0.70 | |
| Revenue Per Share | 0.32 | 0.28 | |
| Ebit Per Revenue | (3.67) | (3.85) |
Currently Active Assets on Macroaxis
When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:Check out Scpharmaceuticals Piotroski F Score and Scpharmaceuticals Altman Z Score analysis. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.95) | Revenue Per Share | Quarterly Revenue Growth 1.641 | Return On Assets | Return On Equity |
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.